- Home
- PCYO vs INBX Comparison
PCYO vs INBX Comparison
Compare PCYO & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PCYO | INBX |
|---|---|---|
| Founded | 1976 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 267.7M | 430.2M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | PCYO | INBX |
|---|---|---|
| Price | $11.05 | $78.97 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 45.7K | ★ 244.6K |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.50 | N/A |
| EPS | ★ 0.54 | N/A |
| Revenue | ★ $26,087,000.00 | $1,400,000.00 |
| Revenue This Year | N/A | $563.00 |
| Revenue Next Year | N/A | $230.77 |
| P/E Ratio | $20.44 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.65 | $10.81 |
| 52 Week High | $12.98 | $94.57 |
Technical Indicators
Market Signals| Indicator | PCYO | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 40.94 | 49.75 |
| Support Level | $11.39 | $76.22 |
| Resistance Level | $11.87 | $94.57 |
| Average True Range (ATR) | 0.37 | 7.36 |
| MACD | -0.09 | -1.30 |
| Stochastic Oscillator | 2.62 | 28.13 |
Price Performance
Historical ComparisonAbout PCYO Pure Cycle Corporation
Pure Cycle Corp is a diversified land and water resource development company. The company designs, constructs, manages, operates, and maintains water and wastewater systems. The firm operates in two business segments namely Water and wastewater resource development and Land development. It generates maximum revenue from the Land development segment. The land resource development segment includes all the activities necessary to develop and sell finished lots.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.